Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 337

1.

Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.

Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO, et al.

Synapse. 1992 Mar;10(3):177-84.

PMID:
1532675
2.

Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors.

Kessler RM, Votaw JR, de Paulis T, Bingham DR, Ansari MS, Mason NS, Holburn G, Schmidt DE, Votaw DB, Manning RG, et al.

Synapse. 1993 Nov;15(3):169-76.

PMID:
8278895
3.

In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.

Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, de Bruin K, van Royen EA.

Int J Rad Appl Instrum B. 1991;18(8):837-46.

PMID:
1839302
4.

In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.

Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.

J Cereb Blood Flow Metab. 2001 Jan;21(1):92-7.

PMID:
11149673
5.

High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain.

Kessler RM, Votaw JR, Schmidt DE, Ansari MS, Holdeman KP, de Paulis T, Clanton JA, Pfeffer R, Manning RG, Ebert MH.

Life Sci. 1993;53(3):241-50.

PMID:
8321085
6.

SPECT imaging of striatal dopamine release after amphetamine challenge.

Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, et al.

J Nucl Med. 1995 Jul;36(7):1182-90.

8.

Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.

Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.

J Nucl Med. 1996 Jan;37(1):11-5.

9.

Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients.

Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB.

Am J Psychiatry. 2000 Jul;157(7):1108-14.

PMID:
10873919
10.

High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.

Kessler RM, Ansari MS, Schmidt DE, de Paulis T, Clanton JA, Innis R, al-Tikriti M, Manning RG, Gillespie D.

Life Sci. 1991;49(8):617-28.

PMID:
1830917
11.
12.

Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM.

Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO, et al.

J Nucl Med. 1992 Nov;33(11):1964-71.

13.

Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.

Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW.

Synapse. 1997 Jan;25(1):1-14.

PMID:
8987142
14.

Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.

Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederen E, Virgolini I, Poewe W, Wenning GK.

Neuroimage. 2005 Feb 1;24(3):822-31. Epub 2004 Nov 24.

PMID:
15652317
15.

Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor.

al-Tikriti MS, Baldwin RM, Zea-Ponce Y, Sybirska E, Zoghbi SS, Laruelle M, Malison RT, Kung HF, Kessler RM, Charney DS, et al.

Nucl Med Biol. 1994 Feb;21(2):179-88.

PMID:
9234281
16.

Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist.

Singhaniyom W, Tsai YF, Brücke T, McLellan CA, Cohen RM, Kung HF, Chiueh CC.

Brain Res. 1988 Jun 21;453(1-2):393-6.

PMID:
2969766
17.

Long-term treatment with the tetrahydropyridine analog (HPTP) of haloperidol influences dopamine ligand binding in baboon brain. An [123I]iodobenzamide (IBZM) SPECT study.

Van der Schyf CJ, Dormehl IC, Oliver DW, Hugo N, Keeve R, Müller-Gärtner HW, Pond SM, Castagnoli N Jr.

Brain Res Mol Brain Res. 1996 Dec 31;43(1-2):251-8.

PMID:
9037540
18.

Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine.

Castner SA, al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB, Goldman-Rakic PS.

Neuropsychopharmacology. 2000 Jan;22(1):4-13.

19.

Effects of reserpine treatment on the dopamine receptor binding of [3H/11C]nemonapride in the mouse and rat brain.

Ishiwata K, Onoguchi K, Toyama H, Noguchi J, Senda M.

Ann Nucl Med. 1997 Feb;11(1):21-6.

PMID:
9095318
20.

Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.

Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.

J Nucl Med. 1998 Jul;39(7):1138-42.

Supplemental Content

Support Center